Skip to main
TIL
TIL logo

Instil Bio (TIL) Stock Forecast & Price Target

Instil Bio (TIL) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 20%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

Instil Bio Inc. has witnessed a significant increase in its stock price, attributed to the positive unveiling of the full HARMONi-2 dataset, reflecting a nearly 500% valuation boost and suggesting potential future momentum with upcoming data from Summit Therapeutics. The company's DCF analysis estimates a firm value of approximately $884 million, underpinned by its innovative cell therapy pipeline which includes ITIL-306, a promising candidate targeting multiple solid tumors. Furthermore, Instil Bio's strategic positioning within the competitive landscape, particularly its pioneering efforts in combining checkpoint inhibition with anti-angiogenesis approaches, reinforces the potential for substantial growth and value generation.

Bears say

Instil Bio reported a net loss of $1.82 for the fourth quarter of 2024 and anticipates a significant increase in its 2025 net loss, projecting it to reach $11.51 per share, compared to a prior estimate of $3.65 per share. The company faces multiple risks that could hinder its prospects, including potential delays in clinical assessments of its candidates and a failure to produce favorable clinical data, especially concerning the AXN-2510 drug in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Additionally, there is a concern regarding medium- to long-term dilution risk, which could negatively impact shareholder value.

Instil Bio (TIL) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 20% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Instil Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Instil Bio (TIL) Forecast

Analysts have given Instil Bio (TIL) a Buy based on their latest research and market trends.

According to 5 analysts, Instil Bio (TIL) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Instil Bio (TIL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.